Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $10.25, but opened at $10.00. Pharming Group shares last traded at $9.91, with a volume of 6,654 shares changing hands.
Pharming Group Stock Performance
The company's fifty day moving average price is $10.65 and its 200 day moving average price is $9.44. The company has a market cap of $688.53 million, a PE ratio of -50.25 and a beta of 0.02. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.76 and a quick ratio of 2.00.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. The company had revenue of $79.09 million during the quarter, compared to the consensus estimate of $67.74 million. Pharming Group had a negative net margin of 4.14% and a negative return on equity of 6.01%. On average, equities research analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current year.
Institutional Trading of Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 52,147 shares of the company's stock after buying an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.08% of Pharming Group worth $557,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.03% of the company's stock.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access Sale